20/20 GeneSystems, Inc
20/20 GeneSystems commercializes innovative biomarker tests to detect early stage cancer & to personalize targeted cancer therapies.
In 2012 we launched a blood test for the early detection of lung cancer. Primary care physicians draw blood samples from patients at risk for the disease due to smoking history and send the sample to our lab. We report a biomarker based risk assessment so that the higher risk patients are followed up with a CT scan. In 2013 and 2014 we plan to launch tests to predict the response of kidney and breast tumors to approved targeted therapies.